Necrotizing Enterocolitis clinical trials at UCLA
1 research study open to eligible people
open to all eligible people
IBP-9414 will be evaluated in preterm infants with a birth weight of 500-1500g, compared to placebo with regards to efficacy and safety in the prevention of necrotizing enterocolitis.
Los Angeles, California and other locations
Our lead scientists for Necrotizing Enterocolitis research studies include Meena Garg.